Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 3, pp. 223-223
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 532-532
Open Access | Times Cited: 80
Polyphenols as Potent Epigenetics Agents for Cancer
Peramaiyan Rajendran, Salaheldin Abdelsalam, Kaviyarasi Renu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11712-11712
Open Access | Times Cited: 60
Thymoquinone, piperine, and sorafenib combinations attenuate liver and breast cancers progression: epigenetic and molecular docking approaches
Ashraf A. El‐Shehawy, Alaa Elmetwalli, Ali H. El‐Far, et al.
BMC Complementary Medicine and Therapies (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 30
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
Medical Oncology (2024) Vol. 41, Iss. 4
Closed Access | Times Cited: 12
Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease
Gabriella Assante, Sriram Chandrasekaran, Stanley Ng, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 23
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
Iason Psilopatis, Nikolaos Garmpis, Anna Garmpi, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2222-2222
Open Access | Times Cited: 16
Seedless black Vitis vinifera polyphenols suppress hepatocellular carcinoma in vitro and in vivo by targeting apoptosis, cancer stem cells, and proliferation
Nadia Z. Shaban, Walaa Hegazy, Marwa M. Abu‐Serie, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116638-116638
Open Access | Times Cited: 6
Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview
Raluca-Margit Szilveszter, Mara Muntean, Adrian Florea
Biomolecules (2024) Vol. 14, Iss. 6, pp. 656-656
Open Access | Times Cited: 5
The black Vitis vinifera seed oil saponifiable fraction ameliorates hepatocellular carcinoma in vitro and in vivo via modulating apoptosis and ROS/NF-κB signaling
Nadia Z. Shaban, Ashraf A. El-Faham, Marwa M. Abu‐Serie, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116215-116215
Open Access | Times Cited: 4
Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
Nikolaos Garmpis, Christos Damaskos, Dimitrios Dimitroulis, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 10, pp. 1672-1672
Open Access | Times Cited: 17
c-FLIP/Ku70 complex; A potential molecular target for apoptosis induction in hepatocellular carcinoma
Yasamin Haghir-Sharif-Zamini, Arezoo Khosravi, Moustapha Hassan, et al.
Archives of Biochemistry and Biophysics (2025), pp. 110306-110306
Closed Access
Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review
Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14117-14117
Open Access | Times Cited: 13
RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
Kurt Sartorius, Samuel O. Antwi, Anil A. Chuturgoon, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Virtual screening, molecular docking, molecular dynamics and quantum chemical studies on (2-methoxy-4-prop-2-enylphenyl) N -(2-methoxy-4-nitrophenyl) carbamate: a novel inhibitor of hepatocellular carcinoma
T. Rajesh Kumar, R. Premkumar, Langeswaran Kulanthaivel, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 23, pp. 13595-13604
Closed Access | Times Cited: 5
LINC00659 Inhibits Hepatocellular Carcinoma Malignant Progression by Blocking Aerobic Glycolysis through FUS Recruitment and SLC10A1 Modulation
Bin Chen, Xin Xu, Wei Wu, et al.
Analytical Cellular Pathology (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 5
DNA methylation mediated downregulation of histone H3 variant H3.3 affects cell proliferation contributing to the development of HCC
Divya Reddy, Saikat Bhattacharya, Sanket Shah, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1868, Iss. 1, pp. 166284-166284
Open Access | Times Cited: 9
L-Selenocysteine induced HepG-2 cells apoptosis through reactive oxygen species-mediated signaling pathway
Kaiying Zhang, Jingyao Su, Danyang Chen, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 9, pp. 8381-8390
Closed Access | Times Cited: 6
Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
Sofia I. Bär, Alexandra Dittmer, Bianca Nitzsche, et al.
International Journal of Oncology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 4
The Role of SNHG15 in the Pathogenesis of Hepatocellular Carcinoma
Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 5, pp. 753-753
Open Access | Times Cited: 4
Role of histone deacetylase inhibitors in diabetic cardiomyopathy in experimental models (Review)
Anna Garmpi, Christos Damaskos, Nikolaos Garmpis, et al.
Medicine International (2022) Vol. 2, Iss. 4
Open Access | Times Cited: 4
Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future
Sultan Nacak Baytaş, Noor-ul-Huda Butt
Current Pharmaceutical Design (2022) Vol. 29, Iss. 1, pp. 2-14
Closed Access | Times Cited: 4
Polymorphisms Related to Iron Homeostasis Associate with Liver Disease in Chronic Hepatitis C
Anna Wróblewska, Anna Woziwodzka, Magda Rybicka, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1710-1710
Open Access | Times Cited: 2
Effects of plasma-derived exosomes from the normal and thin Bactrian camels on hepatocellular carcinoma and their differences at transcriptome and proteomics levels
Hongqiang Yao, Siriguleng Yu, Yuchen Luo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 1
Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer
Rehab Hegazy, Drishti Rathod, Aishwarya Saraswat, et al.
Journal of Molecular Liquids (2024) Vol. 398, pp. 124263-124263
Closed Access
Page 1 - Next Page

Scroll to top